ATR

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Friday, March 15, 2024
Class Action Lawsuit, Professional Services, Legal, ATR, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).
  • Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Global Low Carbon (Green, Blue) Ammonia Industry Research 2024: Focus on United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Carbon, Proton, Growth, Country, Steam, Transport, Porter's five forces analysis, SWOT, ATR, Refrigeration, Carbon footprint, CBAM, European, Hydrogen, SMR, Chemical industry, Alkaline water electrolysis, USD, Fertilizer, Power, Mining

The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.

Key Points: 
  • The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.
  • The report analyses the Low Carbon Ammonia Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India).
  • Japan and South Korea have set ambitious targets for the use of low carbon hydrogen and ammonia in their national energy strategies.
  • The report analyses the Low Carbon Ammonia Market By End-Use (Industrial Feedstock, Power Generation, Transportation, and Other End-Uses).

Radix Launches Resident Portal to Deliver Pricing Data to Renters

Retrieved on: 
Tuesday, April 2, 2024
Research, ATR, Advertising, AI

SCOTTSDALE, Ariz., April 2, 2024 /PRNewswire-PRWeb/ -- Radix, a pioneer in multifamily market research, performance, and data analytics, announces the launch of its Radix Resident Portal, a groundbreaking public data platform aimed at enhancing consumer visibility into property data.

Key Points: 
  • SCOTTSDALE, Ariz., April 2, 2024 /PRNewswire-PRWeb/ -- Radix , a pioneer in multifamily market research, performance, and data analytics, announces the launch of its Radix Resident Portal, a groundbreaking public data platform aimed at enhancing consumer visibility into property data.
  • "Our aim with the resident portal is to empower consumers with enhanced market visibility, illuminate prevailing concessions, and champion economic empowerment," remarked Radix CEO Blerim Zeqiri.
  • In a bid to foster economic liberty while making markets more dynamic, Radix champions data accessibility, dismantling the barriers that hinder market efficiency.
  • Now, with the introduction of the Radix Resident Portal, renters gain access to this invaluable data, facilitating streamlined price discovery, spotlighting concessions and discounts, and facilitating the discovery of rental options tailored to their specific needs.

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Retrieved on: 
Monday, March 11, 2024
Cyclin, Exchange, Prospectus, APRE, DNA, Cyclin E, Sale, Breast, WEE1, DDR, Therapy, Patient, United, Security (finance), IND, Synthetic lethality, ATR, VWAP

DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain Company insiders to raise up to $34.0 million in gross proceeds, including initial upfront funding of $16.0 million and up to an additional $18.0 million upon cash exercise of accompanying warrants at the election of the investors.

Key Points: 
  • “This meaningful financing led by high quality healthcare institutions will support Aprea in our goal to be a leader in the field of Synthetic Lethality (SL) and DNA Damage and Response (DDR),” said Dr. Oren Gilad, President and CEO of Aprea.
  • The private placement is expected to close on or about March 13, 2024 subject to satisfaction of customary closing conditions.
  • Aprea intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051, the Company’s WEE1 inhibitor product candidate which recently received IND clearance.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Bragar Eagel & Squire, P.C. Is Investigating Thoughtworks, Chemours, Methanex, and Inari Medical and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024
The Company, Investigation, Acquisition, Methanex, Annual report, CID, News, Chemours, Audit committee, Justice, Thoughtworks, G3, Security (finance), Methanol, Meal, Bank statement, ATR, CC, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • For more information on the Chemours investigation go to: https://bespc.com/cases/CC
    On February 20, 2024, Methanex issued a press release “announc[ing] .
  • The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals (“HCPs”).
  • For more information on the Inari Medical investigation go to: https://bespc.com/cases/NARI

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

Retrieved on: 
Thursday, March 7, 2024
News, Pomerantz, ATR

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX).
  • The investigation concerns whether Repare and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Methanex Corporation - MEOH

Retrieved on: 
Thursday, March 7, 2024
Pomerantz, Methanex, Prior, News, G3, Methanol, ATR

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Methanex Corporation (“Hesai” or the “Company”) (NASDAQ: MEOH).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Methanex Corporation (“Hesai” or the “Company”) (NASDAQ: MEOH).
  • The investigation concerns whether Methanex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Annual general meeting, WEE1, APRE, Therapy, AACR, ATR

DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting , to take place April 5 to 10, 2024 in San Diego, CA.

Key Points: 
  • DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting , to take place April 5 to 10, 2024 in San Diego, CA.
  • The posters will cover ATRN-119, Aprea’s novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase.

Kirby McInerney LLP is Investigating Shareholder Claims Against Methanex Corp. (MEOH)

Retrieved on: 
Friday, March 1, 2024
News, Methanol, ATR, Methanex, G3, Private investigator

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Methanex Corp. (“Methanex” or the “Company”) (NASDAQ: MEOH ).

Key Points: 
  • NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Methanex Corp. (“Methanex” or the “Company”) (NASDAQ: MEOH ).
  • The ongoing investigation concerns whether Methanex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The time required to replace the structures was expected to delay commercial production up to the end of the third quarter of 2024.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Bragar Eagel & Squire, P.C. Is Investigating Chemours, Methanex, and AirSculpt and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Methanex, Research, News, Chemours, G3, Methanol, ATR, CC, P.C, Audit

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • For more information on the Chemours investigation go to: https://bespc.com/cases/CC
    On February 20, 2024, Methanex issued a press release “announc[ing] .
  • For more information on the Methanex investigation go to: https://bespc.com/cases/MEOH
    Fuzzy Panda Research issued a report Friday alleging issues at AirSculpt Technologies, Inc.